Finance

Lilly to Acquire Kelonia for Up to $7B to Add In Vivo CAR-T

Eli Lilly is set to buy Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront. The deal would add Kelonia’s in vivo CAR-T platform, which reprograms T-cells inside the body, to Lilly’s oncology lineup, with milestones tied to clinical and regulatory progress. Closing is targeted for the second half of 2026.

📅 April 20, 2026
⏱️ 2 min read
Lilly to Acquire Kelonia for Up to $7B to Add In Vivo CAR-T

Key Takeaways

  • Total deal value up to $7B with a $3.25B upfront and milestone-based payments.
  • Deal is expected to close in the second half of 2026.
  • Kelonia's in vivo CAR-T delivers intravenously as a one-time treatment, reprogramming T-cells inside the body.
  • The deal broadens Lilly's hematology offerings beyond ex vivo CAR-T and signals stronger pharma M&A activity in oncology.

People Involved

  • Jacob Van Naarden Lilly Executive

Entities Involved

  • Eli Lilly and Company (Lilly) Global pharmaceutical company pursuing oncology expansion
  • Kelonia Therapeutics Biotech developing in vivo CAR-T therapies
  • Johnson & Johnson Competitor in CAR-T with Carvykti
  • Gilead Sciences, Inc. Acquirer of Arcellx (anito-cel) in CAR-T space

MarketMoodz Analysis

For investors, the Lilly-Kelonia deal signals a committed push into next-generation cell therapies, with a milestone-driven payment structure that balances upfront risk with upside as Kelonia advances clinical milestones. If in vivo CAR-T proves durable and scalable, Lilly could shorten manufacturing timelines and broaden use cases beyond academic centers, potentially accelerating top-line growth in hematology-oncology.

Historically, CAR-T has centered on ex vivo approaches—cell engineering in a lab with complex manufacturing. Kelonia’s in vivo model represents a strategic pivot that, if successful, could reshape the competitive landscape and justify higher deal multiples amid a crowded biotech M&A market. The presence of peers like J&J and Gilead, each pursuing next-generation CAR-T or cell therapies, underscores a broader appetite for oncology-focused deals in 2026.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial